Scinovex
paratext Open Access

Untitled

Jaswir SinghGursharan SinghManpreet SodhiV TubmanE FungM VogiatziA ThompsonZ RogersE NeufeldS ChateGm1 MokhtarM GadallahEl SherifN AliHC Borgna-PignattiM CappelliniDe StefanoPDel NecchioG ForniG GamberiniMC LiC LukS LingK ChinkH YuenC LiC Borgna-PignattiS RougolottoDe StefanoP ZhaoH CappelliniMDel VechhioGK BayanzayL AlzoebieN OliveriD NathanJ MacmillanA WayneLuippA McgeeC Borgna-Pignatti

Abstract

This retrospective review study was conducted on 227 children registered to Thalassemia unit, Rajindra Hospital /Government College Patiala to study increasing age of survival. Demographic details of patients were recorded along with type of chelating agent being used on predesigned proforma. Data of these children was compared with that of year 2008 and 2009.In 2018, maximum number of children were in age group of 5-10 years. Mean age was 10.75 years and median was 10 years (range 1.0-29 years). Ten children were above age of 21 years. In 2008, no child was above age of 21 years. Males outnumber females overall in all years under comparison, but females had better survival above the age of 21 years in 2018.Maximum number of children were on iron chelating agents in 2018 as compared to previous years. With regular transfusion and use of chelating agents, there is increase in survival age of thalassemia children.

Mathematics
Citations
0
FWCI
field-weighted impact
References
5
Percentile
vs. same field & year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.